NCT07210593

Brief Summary

This is a pilot and feasibility study for a mobile phone-delivered intervention, called STRIDE (STrong Relationships to Improve DiabEtes), designed to provide support for adults with type 2 diabetes (improve glycemic management and social support). The goal of the study is to examine the feasibility and acceptability of STRIDE.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable type-2-diabetes

Timeline
9mo left

Started Oct 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress43%
Oct 2025Feb 2027

First Submitted

Initial submission to the registry

September 29, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 7, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

October 15, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

October 20, 2025

Status Verified

October 1, 2025

Enrollment Period

1.3 years

First QC Date

September 29, 2025

Last Update Submit

October 17, 2025

Conditions

Keywords

type 2 diabetesSMART

Outcome Measures

Primary Outcomes (6)

  • Acceptability

    Net Promoter Score with scores ranging 0 to 100 where higher scores (scaled score \>0) indicate good acceptability

    6 months post-baseline

  • Feasibility (Recruitment)

    Number of participants screened/week

    baseline

  • Feasibility (Recruitment)

    Proportion of eligible screens who enroll

    baseline

  • Feasibility (Treatment Adherence)

    Proportion of sessions attended

    6 months post-baseline

  • Feasibility (Treatment Adherence)

    Proportion of interactive texts with response

    6 months post-baseline

  • Feasibility (Assessment Completion)

    Proportion of self-report measures completed

    3 and 6 months post-baseline

Secondary Outcomes (4)

  • Change in Hemoglobin A1c

    Baseline and 3 and 6 months post-baseline

  • Change in Diabetes Distress

    Baseline and 3 and 6 months post-baseline

  • Change in Psychosocial Well-being

    Baseline and 3 and 6 months post-baseline

  • Change in Social Support for Diabetes

    Baseline and 3 and 6 months post-baseline

Study Arms (2)

Experimental: Step 1: Optimal First Line Treatment

EXPERIMENTAL

Persons with diabetes (PWD) participants will first be randomized to an optimal first line treatment in order to compare FAMS vs. PEER. PWD participants assigned to Step 1 treatment "FAMS" will have the option to co-enroll a friend/family member as a support person (SP) to receive text message support tailored to the goal set by the linked PWD. PWD participants assigned to Step 1 treatment "PEER" will be paired with another participant to provide each other peer support.

Behavioral: FAMSBehavioral: PEER

Experimental: Step 2: Optimal Second Line Treatment

EXPERIMENTAL

All PWD participants will be randomized at month 3 to FAMS or PEER. PWD participants assigned to Step 2 treatment "FAMS" will have the option to co-enroll a friend/family member as a support person (SP) to receive text message support tailored to the goal set by the linked PWD if not previously enrolled. PWD participants assigned to Step 2 treatment "PEER" will be paired with another participant to provide each other peer support. If they had previously enrolled a SP, the SP participant will stop receiving text messages.

Behavioral: FAMSBehavioral: PEER

Interventions

FAMSBEHAVIORAL

PWD participants will receive FAMS components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment. Co-enrolled SP participants will receive high-quality print materials upon enrollment and receive text message support tailored to the goal set by the linked PWD.

Experimental: Step 1: Optimal First Line TreatmentExperimental: Step 2: Optimal Second Line Treatment
PEERBEHAVIORAL

PWD participants will receive PEER components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment PWD participants assigned to PEER will be matched with another PWD participant assigned to peer to provide peer support to each other.

Experimental: Step 1: Optimal First Line TreatmentExperimental: Step 2: Optimal Second Line Treatment

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PERSONS WITH DIABETES:
  • Speaks and reads in English
  • years old
  • Diagnosed with type 2 diabetes
  • Receiving outpatient care from a partnering clinic
  • Community-dwelling (e.g., not in a nursing facility)
  • Prescribed at least one daily diabetes medication
  • Owns a mobile phone
  • Elevated diabetes distress or low diabetes self-efficacy
  • Willing to invite a close friend or family member to co-participate
  • SUPPORT PERSONS:
  • Speaks and reads in English
  • years or older
  • Owns a mobile phone

You may not qualify if:

  • PERSONS WITH DIABETES
  • Unable to communicate by phone
  • Currently pregnant
  • Currently undergoing treatment for cancer (e.g., radiation, chemotherapy)
  • Diagnosed with end-stage renal disease
  • Receiving hospice services
  • Diagnosed with congestive heart failure
  • Diagnosed with dementia
  • Diagnosed with schizophrenia
  • Demonstrated an inability to receive and respond to a text
  • Does not take medication on his/her own/medication administered by someone else SUPPORT PERSONS
  • Demonstrated inability to receive \& respond to a text
  • Unable to communicate by phone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
FACTORIAL
Model Details: Sequential Multiple Assignment Randomized Trial (SMART)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

September 29, 2025

First Posted

October 7, 2025

Study Start

October 15, 2025

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

October 20, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share

After study results are posted on clinical trials, de-identified individual and aggregate survey, clinical, and laboratory data (including raw and recoded data) and associated study documentation (survey codebook; analytic code used in survey and clinical data analyses; standard citation and unique identifier to facilitate attribution of data use) will be made publicly available through the Open Science Framework (OSF).

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
After study results are posted on clinical trials (required to occur within 1 year of final data collection), scientific data will be submitted to the Open Science Framework (OSF). Under the current repository policies, data will be preserved and available for the wider research community in perpetuity.
Access Criteria
Survey, clinical, and laboratory data and associated study documentation (survey codebook; analytic code used in survey and clinical data analyses; standard citation and unique identifier to facilitate attribution of data use) will be shared and made publicly available through OSF as open access. Survey, clinical, and laboratory data will be made available in csv and text format and will not require the use of specialized tools to be accessed or manipulated. All shared data and documentation will be findable and identifiable using the standard data indexing tools in Open Science Framework.

Locations